SAMPLE QUERIES
Question from Monsieur P., XYZ Finance Company, Paris :
The production of photovoltaic energy is a fast-growing sector in Europe. Why, in your view, is it particularly strong in Spain ?
To what extent is the European regulatory context going to influence the development of comparable projects elsewhere in Europe ? Who are the people involved ? Who are the likely winners and losers ? What competitive advantages does photovoltaic energy offer, by comparison with wind energy ?
Proposal 1 :
Marc T., 36, Co-founder of TG Investment, an investment company specializing in renewable energy.
Sector : Finance/Energy
Barcelona, Spain
André S., 48, Company X, European leader in wind-energy production in Europe, Development Director of Wind and Photovoltaic Energy for southern Europe.
Sector : Renewable Energy
Toulouse, France
Michel V., 44, Member of the European Parliament, familiar with issues relating to environmental protection.
Sector : Elected Representative/Politics
Brussels, Belgium
Question from Mme L., XYZ Capital Company, Geneva:
In your opinion, what are the segments and developments in the market for industrial and food packaging in France and Italy? What changes can we expect in relation to the important technological developments in this particular area? Proposal 1 :Thierry S., 43, Development Director of Company X, an international leader in food packaging.
Sector : Capital Goods
Lyon, France
Richard B., 57, Development and Purchasing Director, Group X, European leader in dairy ice-cream production.
Sector : Food Processing
Nice, France
Victoria S., 45, Commercial Director, Company Y.
Sector : Capital Goods
Strasbourg, France
Stéphanie S. : CEO, Purchasing Company X, top media agency and leading buyer of advertising in France.
Sector : IT Media
Paris, France
Franck P. : Former CEO of Company X, French leader in search engines.
Bordeaux, France Proposal 3:
Frank D.: Marketing Director at the X Bank, one of the 10 main French advertisers.
Sector : Banking/Marketing
Paris, France
What, in your view, are the repercussions for Pfizer since it suspended development of the ‘Torcetrapib’ (anti-cholesterol) drug following 3 deaths during trials, given that the patent for ‘Lipitor’, its current anti-cholesterol drug, will enter the public domain in 2011 ? Who stands to gain from this situation ? More specifically, can Abbott Laboratories, the company buying out a laboratory producing ‘Niaspan’, a competing product for ‘Lipitor’, benefit from it ?
Proposal 1 :
Dr William F. Cardiologist, Director of Cardiology at the X Hospital, Lecturer at the Medical Faculty of the University of Paris V.
Paris, France
Proposal 2 :
Dr Pierre B, General Practitioner, President of the Ordre des Médecins, (X Region).
Sector : Pharmaceuticals
Toulon, France
Dr. Philippe F, formerly Director of Research at the X laboratories, currently a consultant.
Sector : Pharmaceuticals
Geneva, Switzerland